Ratings by TD Cowen (Stacy Ku)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/26/2026 | BioCryst Pharma | BCRX | Maintain | Buy (N/A) |
|
Details | ||
| 2/25/2026 | Supernus Pharmaceuticals | SUPN | Maintain | (N/A) |
|
Details | ||
| 2/24/2026 | Avalo Therapeutics Inc. | AVTX | Maintain | Buy (N/A) |
|
Details | ||
| 1/29/2026 | Kalvista Pharmaceuticals Inc | KALV | Maintain | Buy (N/A) |
|
Details | ||
| 1/14/2026 | Centessa Pharmaceuticals | CNTA | Maintain | Buy (N/A) |
|
Details | ||
| 1/7/2026 | Verrica Pharmaceuticals | VRCA | Maintain | Buy (N/A) |
|
Details | ||
| 12/12/2025 | BioCryst Pharma | BCRX | Maintain | Buy (N/A) |
|
Details | ||
| 12/3/2025 | Kalvista Pharmaceuticals Inc | KALV | Maintain | Buy (N/A) |
|
Details | ||
| 10/30/2025 | DiaMedica Therapeutics Inc. | DMAC | New Coverage | Buy (N/A) |
6.69 (7.71) |
15.25% | Details | |
| 10/23/2025 | Supernus Pharmaceuticals | SUPN | Maintain | Buy (N/A) |
|
Details | ||
| 10/15/2025 | BioCryst Pharma | BCRX | New Coverage | Buy (N/A) |
7.04 (8.48) |
20.45% | Details | |
| 9/5/2025 | Avalo Therapeutics Inc. | AVTX | New Coverage | Buy (N/A) |
10.16 (17.31) |
70.37% | Details | |
| 8/13/2025 | Verrica Pharmaceuticals | VRCA | Maintain | Buy (N/A) |
|
Details | ||
| 6/30/2025 | Aurinia Pharmaceuticals | AUPH | Maintain | Buy (N/A) |
|
Details | ||
| 5/2/2025 | Grace Therapeutics | GRCE | New Coverage | Buy (N/A) |
2.71 (3.86) |
42.44% | Details | |
| 3/18/2025 | LENZ Therapeutics Inc | LENZ | Upgrade | Buy (N/A) |
25.45 (11.67) |
-54.15% | Details | |
| 3/5/2025 | Centessa Pharmaceuticals | CNTA | Maintain | Buy (N/A) |
|
Details | ||
| 1/7/2025 | Centessa Pharmaceuticals | CNTA | New Coverage | Buy (N/A) |
16.74 (25.95) |
55.02% | Details | |
| 1/7/2025 | Kalvista Pharmaceuticals Inc | KALV | New Coverage | Buy (N/A) |
8.68 (16.23) |
86.98% | Details | |
| 12/5/2024 | Protera Therapeutics | TARA | Maintain | Buy (N/A) |
|
Details | ||
| 11/20/2024 | Astria Therapeutics | ATXS | Maintain | Buy (N/A) |
|
Details | ||
| 10/21/2024 | Verrica Pharmaceuticals | VRCA | Maintain | Buy (N/A) |
|
Details | ||
| 9/25/2024 | Astria Therapeutics | ATXS | Maintain | Buy (N/A) |
|
Details | ||
| 9/9/2024 | Protera Therapeutics | TARA | Maintain | Buy (N/A) |
|
Details | ||
| 8/13/2024 | Astria Therapeutics | ATXS | Maintain | Buy (N/A) |
|
Details | ||
| 8/6/2024 | Protera Therapeutics | TARA | Maintain | Buy (N/A) |
|
Details | ||
| 7/29/2024 | Astria Therapeutics | ATXS | New Coverage | Buy (N/A) |
11.93 (12.58) |
5.45% | Details | |
| 6/25/2024 | BioCryst Pharma | BCRX | Maintain | Buy (N/A) |
|
Details | ||
| 4/5/2024 | Protera Therapeutics | TARA | Maintain | Buy (N/A) |
|
Details | ||
| 2/15/2024 | Aurinia Pharmaceuticals | AUPH | Maintain | Buy (N/A) |
|
Details | ||
| 8/3/2020 | Momenta Pharmaceuticals | MNTA | Upgrade | Buy (Hold) |
29.49 (52.48) |
77.96% | Details |
